Immunoglobulin A Nephropathy (IgAN) is a major cause of kidney disease worldwide and the leading cause of end stage renal disease (ESRD) among Asians. The affected individuals develop IgA1-containing antibody complexes that deposit in the kidney producing tissue injury. An increased serum level of galactose- deficient IgA1 (Gd-IgA1) has emerged as a useful biomarker of IgAN. Gd-IgA1 promotes formation and kidney deposition of IgA1-containing immune complexes, but the reason why IgAN patients have high Gd-IgA1 is not well understood. We have formed a multidisciplinary team of experienced investigators in order to accelerate the discovery of pathogenic mechanisms in IgAN. Through our collaborative efforts, we have already made significant contributions to the field, including the identification of the first Mendelian mutation that affects production of Gd-IgA1 and causes familial IgAN. We also completed a large genome-wide association study of IgAN involving 20,574 individuals and identified 15 common susceptibility alleles associated with disease risk. We observed that the worldwide distribution of common alleles closely parallels the disease epidemiology and that a burden of inherited risk alleles correlates with the age of disease onset. Our findings identify intestinal immunity as the key pathway involved in the disease pathogenesis. In this proposal, we hypothesize that both common and rare genetic variants contribute to the pathogenesis of IgAN and that these variants induce discrete lesions in innate and adaptive immunity, which inexorably lead to the development of kidney injury. We will leverage a large, well-characterized cohort of patients to define the biological and clinical impact of known risk variants and apply exome sequencing to define new genes underlying IgAN. The first part of this proposal will relate the newly discovered genetic factors to immunologic disease features, specific kidney biopsy findings, and clinical parameters of disease severity and progression. These studies are expected to refine the pathogenesis model and will be critical in enhancing the diagnosis and classification of IgAN. The second part of the proposal aims to define additional rare mutations with large effect underlying familial IgAN. Our innovative gene mapping strategy combines family screening for elevated serum Gd-IgA1 levels with exome sequencing to efficiently identify segregating pathogenic variants. We will perform functional analysis of candidate genes using knockdown and overexpression in IgA1-producing cell lines. Finally, we will aim to identify independent pathogenic mutations by sequencing of sporadic individuals with extreme values of Gd-IgA1 levels.

Public Health Relevance

Successful completion of the proposed studies will identify novel mutations underlying the disease, refine the pathogenesis model of IgAN, and provide the knowledge necessary to translate our new genetic discoveries into clinical applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK082753-05
Application #
8839565
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Moxey-Mims, Marva M
Project Start
2009-05-01
Project End
2019-06-30
Budget Start
2014-09-15
Budget End
2015-06-30
Support Year
5
Fiscal Year
2014
Total Cost
$702,756
Indirect Cost
$144,218
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Mestecky, Jiri; Novak, Jan; Moldoveanu, Zina et al. (2016) IgA nephropathy enigma. Clin Immunol 172:72-77
Huang, Zhi Qiang; Raska, Milan; Stewart, Tyler J et al. (2016) Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy. J Am Soc Nephrol 27:3278-3284
Xie, Jingyuan; Kiryluk, Krzysztof; Li, Yifu et al. (2016) Fine Mapping Implicates a Deletion of CFHR1 and CFHR3 in Protection from IgA Nephropathy in Han Chinese. J Am Soc Nephrol 27:3187-3194
Knoppova, Barbora; Reily, Colin; Maillard, Nicolas et al. (2016) The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Front Immunol 7:117
Suzuki, Hitoshi; Allegri, Landino; Suzuki, Yusuke et al. (2016) Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? Dis Markers 2016:7806438
Neprasova, Michaela; Maixnerova, Dita; Novak, Jan et al. (2016) Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study. Dis Markers 2016:3650909
Lai, Kar Neng; Tang, Sydney C W; Schena, Francesco Paolo et al. (2016) IgA nephropathy. Nat Rev Dis Primers 2:16001
Stuchlova Horynova, Milada; Vrablikova, Alena; Stewart, Tyler J et al. (2015) N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant 30:234-8
Zhu, Li; Zhai, Ya-Ling; Wang, Feng-Mei et al. (2015) Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. J Am Soc Nephrol 26:1195-204
Novak, Jan; Rizk, Dana; Takahashi, Kazuo et al. (2015) New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis (Basel) 1:8-18

Showing the most recent 10 out of 63 publications